T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic
07/22/20, 8:09 AM
T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF.
Company Info
Additional Info
AccelFoods is an early-stage venture fund investing in consumer products.
We partner with entrepreneurs to bring innovative, high-quality food and
beverage products to the forefront of the industry and create the next
generation of enduring brands. With nearly $40m under management, we are
hands-on partners that work tactically with our founders to scale their
businesses quickly and smartly. We connect the dots within the broader food
& beverage ecosystem to provide unique access, share distinct expertise,
and build solid infrastructure.